The main department of described Corporate Investor is located in the Palo Alto. The company was established in North America in United States.
The real fund results show that this Corporate Investor is 0 percentage points less often commits exit comparing to other companies. Opposing the other organizations, this Samsara BioCapital works on 1 percentage points more the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 50 - 100 millions dollars. The important activity for fund was in 2019. The increased amount of exits for fund were in 2019.
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Samsara BioCapital, startups are often financed by Alta Partners, Skyline Ventures, SV Health Investors. The meaningful sponsors for the fund in investment in the same round are Redmile Group, EcoR1 Capital, Cormorant Asset Management. In the next rounds fund is usually obtained by UBS Oncology Impact Fund, Redmile Group, EcoR1 Capital.
The overall number of key employees were 2.
We can highlight the next thriving fund investment areas, such as Clinical Trials, Health Care. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline ElevateBio, ElevateBio, AlloVir For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Arno Capital | Israel, Ramat Gan, Tel Aviv |
| Chelsea Vanguard Fund | - |
| Colour Life Services Group | China, Guangdong, Shenzhen |
| Drake Management | New York, Nyack, United States |
| First Check Ventures | - |
| Frontline Ventures | England, London, United Kingdom |
| Grupo Picking Pack | - |
| Hallador Investment Advisors | - |
| Hamilton Ventures LLC | Atlanta, Georgia, United States |
| Hargreave Hale | England, London, United Kingdom |
| Huaxin Zhongcheng Investment | China, Guangdong, Tianjin |
| Kloeckner & Co | Duisburg, Germany, Nordrhein-Westfalen |
| MOGU | China, Hangzhou, Zhejiang |
| Nirvana Capital | Beijing, Beijing, China |
| Otter Media | California, Santa Monica, United States |
| Sands Brothers Asset Management | New York, New York, United States |
| Shenzhen Huijing Tongda Business Consulting | China, Guangdong, Shenzhen |
| Tennant Capital Partners | Missouri, Saint Louis, United States |
| UNT Group | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Alpha9 Theranostics | 23 Oct 2024 | Vancouver, British Columbia, Canada | |||
Enara Bio | 03 Oct 2024 | London, England, United Kingdom | |||
Nura Bio | $68M | 17 Sep 2024 | South San Francisco, California, United States | ||
Candid Therapeutics | $370M | 09 Sep 2024 | San Diego, California, United States | ||
OrsoBio | $67M | 06 Sep 2024 | Palo Alto, California, United States | ||
Pathalys Pharma | $105M | 20 Aug 2024 | Raleigh, North Carolina, United States | ||
Autobahn Therapeutics | $100M | 24 Jul 2024 | San Diego, California, United States | ||
Enlaza Therapeutics | $100M | 30 Apr 2024 | La Jolla, California, United States | ||
Obsidian Therapeutics | $160M | 03 Apr 2024 | Cambridge, Massachusetts, United States |
– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.
– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Alpha9 Theranostics | 23 Oct 2024 | Vancouver, British Columbia, Canada | |||
Enara Bio | 03 Oct 2024 | London, England, United Kingdom | |||
Nura Bio | $68M | 17 Sep 2024 | South San Francisco, California, United States | ||
Candid Therapeutics | $370M | 09 Sep 2024 | San Diego, California, United States | ||
OrsoBio | $67M | 06 Sep 2024 | Palo Alto, California, United States | ||
Pathalys Pharma | $105M | 20 Aug 2024 | Raleigh, North Carolina, United States | ||
Autobahn Therapeutics | $100M | 24 Jul 2024 | San Diego, California, United States | ||
Enlaza Therapeutics | $100M | 30 Apr 2024 | La Jolla, California, United States | ||
Obsidian Therapeutics | $160M | 03 Apr 2024 | Cambridge, Massachusetts, United States |
